As such, concurrent targeting of various forms of mutant KRAS and individual members of the miRNA biogenesis and processing machinery might represent a synergistic therapeutic strategy to treat several types of cancer with KRAS mutation [181]. This evidence concerns the gene KRAS and cancer.